Anti-NMDA receptor encephalitis

Myrna R Rosenfeld MD PhD (

Dr. Rosenfeld received royalties from Euroimmun for intellectual property rights.

Josep Dalmau MD PhD (

Dr. Dalmau of IDIBAPS, University of Barcelona, received royalties from Euroimmun for intellectual property rights.

Francesc Graus MD PhD, editor. (Dr. Graus of the University of Barcelona has no relevant financial relationships to disclose.)
Originally released September 2, 2018; last updated June 4, 2020; expires June 4, 2023


Anti-NMDA receptor encephalitis is an autoimmune disorder that affects people of all ages, but predominantly young women (about 50% with an associated ovarian teratoma) and children of both sexes. Patients present with neuropsychiatric manifestations and memory and cognitive deficits and usually progress to catatonia, seizures, autonomic dysfunction, stereotypic movements, and coma. Recovery can be prolonged. The diagnosis can be strongly suspected by history and clinical evaluation and confirmed by detection of CSF IgG antibodies to the GluN1 subunit of the NMDA receptor. Patients often respond to a combination of immunotherapy, including corticosteroids, IVIg or plasma exchange, and/or rituximab or cyclophosphamide.

Key points


• Anti-NMDA receptor encephalitis is mediated by specific IgG autoantibodies to the GluN1 subunit of the NMDA receptor.


• Most patients present with neuropsychiatric symptoms that progress to include seizures, movement disorders, autonomic dysfunction, and decreased level of consciousness.


• The underlying mechanism of the disorder is a reversible antibody-mediated reduction of synaptic NMDA receptors.


• Almost 80% of patients have full or substantial recovery with early initiation of immunotherapy, and removal of an associated tumor, if present (usually ovarian teratoma), is associated with better outcomes.

Historical note and terminology

In 2005, 4 young women with ovarian teratoma and subacute psychiatric symptoms, seizures, decreased level of consciousness, and frequent central hypoventilation of unknown etiology were reported (Vitaliani et al 2005). The patients had inflammatory abnormalities in the cerebrospinal fluid, and all improved after tumor resection, immunotherapy, or both. This supported a paraneoplastic etiology, but some of the teratomas were benign and none of the patients had paraneoplastic (onconeural) antibodies, which target intracellular neuronal antigens (Graus et al 2004). Rather, all had an immune response targeting an antigen enriched in the neuropil of the hippocampus that was subsequently identified to be the N-methyl-D-aspartate (NMDA) receptor (Dalmau et al 2007). The response to immunotherapy and the location and function of the NMDA receptor suggested that the disorder, now called anti-NMDA receptor encephalitis, was mediated by the antibodies. Using the presence of the antibodies as a diagnostic test, it soon became clear that this disorder occurs with and without a tumor association and can occur in men (Dalmau et al 2008). It was also shown that similar previously reported cases (some grouped under the term “acute nonherpetic encephalitis of juvenile onset”) were, in fact, cases of anti-NMDA receptor encephalitis (Kamei et al 2009). The characterization of anti-NMDA receptor encephalitis led to the identification of other encephalitic syndromes, each associated with a specific pathogenic autoantibody that targets neuronal receptors, channels, or synaptic proteins (Dalmau and Graus 2018). This group of disorders is now often referred to as “antibody-mediated encephalitis” or “autoimmune encephalitis.”

The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.

If you are a subscriber, please log in.

If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.

If you have never registered before, click Learn More about MedLink Neurology  or view available Service Plans.

Find out how you can join MedLink Neurology